Description
Oczyesa is a medicine used for the maintenance (long-term) treatment of acromegaly, a condition
where a pituitary adenoma (a non-cancerous tumour in a small gland located at the base of the brain)
produces too much growth hormone causing high levels of insulin-like growth factor-1 (IGF-1). This
leads to excessive growth of tissues and bones and can also cause diabetes, hypertension (high blood
pressure) and cardiovascular disease (conditions affecting the heart and blood circulation).
Oczyesa is used in adults who have previously responded to and tolerated treatment with other
somatostatin analogues (man-made (synthetic) versions of the hormone somatostatin).
Oczyesa contains the active substance octreotide and is a ‘hybrid medicine’. This means that it is
similar to a reference medicine containing the same active substance, but there are certain differences
between the two. The reference medicine for Oczyesa is Sandostatin, which is available as a solution
for injection at lower strengths than Oczyesa and is also authorised for the treatment of acromegaly.
Oczyesa (octreotide)
See full prescribing information : Click Here
Get Access To Oczyesa (octreotide) Injection In India On Request
Oczyesa® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Oczyesa prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838.
Apart from Gulf countries, Oczyesa® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). South Delhi Pharma can help facilitate the legal supply of Oczyesa® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.